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Abstract
Background: Glucocorticoids are important in the treatment of childhood acute lymphoblastic
leukaemia (ALL). However, cyclic administration of high dose glucocorticoids may cause rapid and
substantial changes in quality of life (QoL). The maintenance phase of the Dutch ALL-9 protocol
consisted of alternating two weeks on and five weeks off dexamethasone (6 mg/m2/day). The
present study was performed to assess the effect of dexamethasone on QoL during treatment for
ALL according to this protocol.
Methods: In a multicentre prospective cohort study, QoL was assessed halfway (T1) and at the
end of the two-year treatment (T2). A generic (Child Health Questionnaire) and disease specific
(PedsQL™ cancer version) QoL questionnaire were used to assess QoL in two periods: on and
off dexamethasone, respectively.
Results: 41 children (56% males) were evaluated, mean age at diagnosis was 5.6 years. The CHQ
physical and psychosocial summary scores were significantly lower than population norms. At T1
and T2, overall QoL showed no significant change. However, regarding specific domains (pain,
cognitive functioning, emotion/behaviour and physical functioning) QoL decreased over time. QoL
was significantly more impaired during periods on dexamethasone.
Conclusion: Dexamethasone was associated with decreased QoL. At the end of treatment,
reported QoL during dexamethasone deteriorated even more on certain scales (pain, cognitive
functioning, emotion/behaviour and physical functioning). Knowledge of the specific aspects of QoL
is essential to improve counselling and coping in paediatric oncology. Adverse effects of specific
drugs on QoL should be taken into account when designing treatment protocols.
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Acute Lymphoblastic Leukaemia (ALL) is the most com-
mon form of childhood cancer. Over the past decades sur-
vival following treatment for childhood ALL has
improved substantially, now reaching about 80%. With
increased survival rates, issues concerning the Quality of
Life (QoL) of these children become increasingly relevant.
This is reflected in the steady rise in studies concerning
QoL. Most of these studies have focused on the follow-up
of childhood cancer survivors and, to a lesser extend, on
children during active treatment. It seems most children
experience reduced QoL during and after treatment. [1-4]
More attention to treatment related factors of decreased
QoL may provide health-care workers with specific tools
to address these issues.
Glucocorticoids are an important drug in current ALL
therapy. They induce apoptosis and glucocorticoid
responsiveness is an early indicator of response to chem-
otherapy in general. Most treatment protocols include
glucocorticoids during induction, reinduction and/or
maintenance therapy. Dexamethasone has proven supe-
rior over prednisone, reducing relapse rate and improving
event free survival [5-8], although there is evidence it
might cause more side-effects. [7]
Studies on glucocorticoid-related psychosocial morbidity,
although often clinically evident, in children are sparse. A
review on this subject by Stuart et al. [9] in 2005, yielded
ten larger studies, only two of which concerned childhood
ALL, and several case-reports. Possible steroid-related side
effects include emotional lability, anxiety, aggressive
behaviour, hyperactivity, depression [10,11], problems
with concentration, excessive eating [12], increase in pain
[13] and sleep disorders [14]. These side-effects can seri-
ously affect QoL. Glucocorticoids are likely to contribute
to the rapid and intensive changes in QoL, mood and
behaviour during ALL therapy. [13,15]
The aim of this study was to assess the effect of dexameth-
asone on QoL during maintenance treatment in children
with ALL. Based on clinical experience and previous stud-
ies, it was hypothesized that QoL was more impaired dur-
ing periods on dexamethasone than during periods
without dexamethasone. [13,15]
Methods
Patients
A prospective, multicentre cohort study was designed.
Children from three different Dutch centres were enrolled
(WKZ Utrecht, AMC Amsterdam and VU University Med-
ical Centre Amsterdam). All children between the ages of
2 and 18 years on active treatment according to the Dutch
Childhood Oncology Group (DCOG) ALL-9 protocol
were eligible. Parents who were not fluent in Dutch were
excluded. Children with an important pre-existing condi-
tion (e.g. Down syndrome) were excluded because of a
potentially different baseline quality of life.
This treatment protocol was open for inclusion from 1996
to 2004. Children with one of the following characteris-
tics at diagnosis were stratified into the High Risk group
(HR): initial leukocyte count >50 × 109/l, presence of
mediastinal enlargement, initial leukaemia of the central
nervous system or testis, presence of t(9;22) or BCR-ABL,
t(4;11) or 11q23 with MLL rearrangement and T-cell
immunophenotype. All other children were classified as
Non-High risk (NHR). Important differences in induction
treatment between both risk groups consisted of total
methotrexate dose (NHR 6000 mg/m2 and HR 12000 mg/
m2). The HR group received two additional intensification
treatment blocks after induction. Maintenance treatment
consisted of five weeks of mercaptopurine and methotrex-
ate alternated with two weeks of 6 mg/m2/day of dexame-
thasone and weekly vincristine. Maintenance treatment
was similar for both groups except for methotrexate,
which was given intravenously for the HR group as
opposed to orally for the NHR group, and frequency of
intrathecal therapy (including age dependent methotrex-
ate dose, NHR four times and HR seven times). Total
duration of therapy was 109 weeks.
Inclusion into the study was halfway through treatment,
whenever possible, allowing for two consecutive measure-
ments: 12 months after the initial diagnosis (T1) and at
the end of the two year treatment (T2). During 18 months
(spring 2005 – fall 2006) all eligible patients were
informed about the study at their paediatric oncology
clinic. Questionnaires were sent by mail together with
written information about the study and a stamped return
envelope. Written informed consent was obtained prior to
inclusion. If questionnaires were not returned within a
month, patients were contacted by one of the researchers.
At T1 and T2 QoL assessment tools were filled out for the
most recent period on dexamethasone and the most
recent period off dexamethasone. Since at the start of this
study recruitment for ALL-9 had ceased and a new treat-
ment protocol had already started, inclusion was maxi-
mized by including all children still treated according to
ALL-9. For some children only measurement at T2 was
possible, because they had already been treated for over a
year when this study opened. The study was approved by
the medical ethical review board.
Measures
Parents (either father or mother) rated their children's
QoL using both a generic and disease specific instrument.
The Dutch version of the Child Health Questionnaire 50
items parent form (CHQ-PF50) is a generic QoL assess-
ment tool and has shown good reliability and validity.Page 2 of 8
(page number not for citation purposes)
Health and Quality of Life Outcomes 2008, 6:103 http://www.hqlo.com/content/6/1/103[16,17] The CHQ has been used in several paediatric
oncology studies. [3,4,18] This instrument covers the
physical, emotional and social well-being of children and
allows for two summary scores (physical and psychoso-
cial). Items are scored using a four to six point Likert scale
and converted to a 0 to 100 point continuum, with higher
scores indicating better QoL. The original reference period
of the CHQ (four weeks) was adjusted to suit the two
week dexamethasone period. Dutch population norms
are available and allow for a comparison with the Dutch
healthy population. [16] The CHQ was designed for chil-
dren five years and up. Although the Infant and Toddler
Quality of Life Questionnaire would have been more
appropriate for the younger children in our study sample
[19], at the time of the design of our study, no validated
Dutch version and norms were available.
The Paediatric Cancer Quality of Life Inventory 3.0™ Acute
Cancer Version (PedsQL) is a cancer specific question-
naire that was translated into Dutch in close corrobora-
tion with the original author. The PedsQL cancer version
has frequently been used in paediatric oncology studies.
[20-22] It has proven a reliable and valid QoL assessment
tool [23] with subscales for determining problems in rel-
evant areas during cancer treatment such as pain, nausea,
treatment and procedural anxiety, worry, cognitive prob-
lems, perceived physical appearance and communication.
Items are scored using a four point Likert scale and reflect
on the past week. Higher scores indicate better QoL. The
scale incorporates age-specific questions and is also avail-
able in a parallel form for children from the age of five
years onwards.
At T1 and T2 the questionnaires for assessment of both
periods on and off dexamethasone, respectively, were sent
in one mailing. Parents were instructed to assess both
periods independently. Children aged 8 years or older
were asked to do the same for the PedsQL only. Five to
seven year olds were felt to be too young to participate,
particularly since the questionnaires were sent to the fam-
ily's homes and researchers were unable to coach the chil-
dren. Although a child version of the CHQ is available
and obtaining self-reports seems preferable whenever pos-
sible, only the PedsQL self-report was used to minimize
patient burden.
Statistics
The Statistical Package for Social Sciences (SPSS) for Win-
dows version 12.0 was used for all the analyses. Differ-
ences in QoL subscale and total scores for periods on and
off dexamethasone were compared using paired t-tests or
Wilcoxon signed ranks tests. Change in QoL scores over
time were also compared using paired t-tests or Wilcoxon
signed ranks tests. The magnitude and meaning of the dif-
ferences in QoL are represented as Cohen's effect size (d).
Effect sizes are calculated as follows: [mean(a) – mean
(b)/largest standard deviation score (SD)], this means that
differences between groups are expressed in units of the
largest within-group standard deviation. Effect size
between 0.2 and 0.5 indicate a small effect, an effect size
between 0.5 and 0.8 indicate a moderate effect, and effect
sizes ≥ 0.8 represent a large effect. [24,25] Differences in
QoL score between treatment groups were compared
using a Mann-Whitney-U test. T-tests were used for com-
parison with CHQ Dutch population norms. Significance
level was set at p < 0.05 for all analyses.
Results
Demographics
A total of 56 children were eligible. All parents were
invited to join this study, 41 (73%) eventually partici-
pated (see Figure 1). No information on the other 15 chil-
dren was available, since no informed consent was
obtained. Mean age at diagnosis was 5.6 years, 56% were
male. 78% of all children were treated according to the
Non-High risk protocol. There was no statistically signifi-
cant difference in age or gender between the High and
Non-High risk group (Table 1). At T1 only five child self
reports were obtained, the other children were too young
to fill out self-reports. These results were therefore omitted
from statistical analysis. At the end of treatment, 12 self
reports were returned. These results were taken into anal-
ysis.
PedsQL acute cancer version, parent-reports
Halfway as well as at the end of treatment, parents rated
their child's overall QoL to be more impaired during peri-
ods on dexamethasone as compared to periods off dexam-
ethasone. This also applied to most of the PedsQL
subscales (see Table 2). The effect size of the difference in
score between periods on and off dexamethasone on the
pain subscale was 0.88 at T1 and 0.91 at T2, indicating
more pain during the use of dexamethasone and repre-
Table 1: Demographics
Total Non-High Risk High Risk p
N 41 32 (78%) 9 (22%)
Males (%) 23 (56%) 18 (78%) 5 (56%) NS
Mean age (yrs) at diagnosis (SD) 5.6 (3.3) 5.8 (3.5) 4.9 (2.6) NSPage 3 of 8
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the total score (T1 d = 0.58; T2 d = 0.47) and the cognitive
subscale (T1 d = 0.53; T2 d = 0.78). Comparing both time
points (T1 and T2) overall QoL remained stable, except
for the subscales of pain (p = 0.01; d = 0.44) and cognitive
problems (p = 0.03; d = 0.42), for which the adverse effect
of dexamethasone was more pronounced at T2. Problems
in the area of perceived physical appearance worsened
over time for the periods off dexamethasone (p = 0.03; d
= 0.34).
Except for children in the HR group, who experienced
more cognitive problems (both on and off dexametha-
sone) at the end of treatment, there were no differences
between both risk groups. Mean score at T2 on the cogni-
tive subscale during dexamethasone was 34.0 (SD 24.0)
for the HR group and 59.3 (SD 21.3) for the NHR group
(p = 0.05). Off dexamethasone mean scores were 59.1 (SD
21.1) for the HR group and 77.8 (SD 17.1) for the NHR
group (p = 0.03). Effect sizes were large (dexamethasone
d = 1.05; off dexamethasone d = 0.89).
PedsQL acute cancer version, child-reports
At T2, there was a non significant trend that children also
judged their own overall QoL to be worse during periods
on dexamethasone (see table 3). At T2 during dexameth-
asone, scores on the PedsQL were significantly lower for
the subscales pain (p = 0.04; d = 0.70), worry (p = 0.02; d
= 0.50) and cognition (p = 0.01; d = 0.67). Nausea was
scored significantly better (p = 0.04), although the effect
size was small (d = 0.15). Because of the small sample size,
no statistically significant differences between parent and
child rating of QoL could be demonstrated. For both peri-
ods on and off dexamethasone, there was a significant
positive correlation between parent and child answers (on
dexamethasone r = 0.76 [p < 0.001] and off dexametha-
sone r = 0.81 [p < 0.001]).
CHQ-PF50
The CHQ physical summary score (PhS) and psychosocial
summary score (PsS) were significantly lower than Dutch
population norms (see table 4), except for the PsS at T1
during the dexamethasone free period. QoL was signifi-
cantly more impaired during periods on dexamethasone
for both PhS and PsS, and for most subscales. The clinical
significance of these differences is reflected in mostly large
effect sizes (see table 4). Over time, QoL became more
impaired for some aspects as measured by the CHQ. At T2
during periods on dexamethasone, children scored worse
on the physical summary scale (d = 0.57) and the sub-
scales of family cohesion (d = 0.67) and emotional/
behavioural role limitation (d = 0.58). Scores on the sub-
Study participationFigure 1
Study participation. * no participation at T2 because of: 
recurrence of leukaemia (n = 1) and not returning the ques-
tionnaires at T2 (n = 1). ** n = 2 were not treated with dex-
amethasone anymore because of serious corticosteroid 
related complications and only returned the off dexametha-
sone questionnaire.
Table 2: PedsQL™ 3.0 acute cancer module Parent Form
T1 (n = 15) T2 (n = 37)
Dexa + Mean (SD) Dexa – Mean (SD) Effect size1 p2 Dexa + Mean (SD) Dexa – Mean (SD) Effect size1 p3
Total 68.0 (15.6) 77.0 (8.5) -0.58 0.01 66.2 (14.6) 73.1 (13.1) -0.47 <0.01
Pain 53.3 (21.9) 72.6 (15.1) -0.88 0.02 41.9* (26.2) 65.9 (21.8) -0.91 <0.01
Nausea 74.5 (21.7) 75.0 (17.3) 0.02 NS 73.9 (22.4) 67.0 (22.1) 0.30 0.04
Procedural Anxiety 55.6 (33.7) 63.3 (27.4) -0.23 0.03 71.2(29.3) 75.5 (24.2) -0.15 NS
Treatment Anxiety 75.0 (30.7) 83.3 (25.0) -0.27 0.04 80.6 (22.8) 84.5 (22.4) -0.17 NS
Worry 86.1 (23.5) 87.2 (15.1) -0.05 NS 69.4 (29.7) 76.4 (24.9) -0.24 NS
Cognitive 66.2 (27.5) 80.8 (17.4) -0.53 NS 54.6* (23.2) 72.8 (19.7) -0.78 <0.01
Physical appearance 65.6 (28.3) 77.8 (19.3) -0.43 0.03 62.1 (27.6) 69.3* (24.9) -0.26 <0.01
Communication 62.0 (39.3) 75.1 (28.7) -0.33 0.03 67.1 (28.5) 75.6 (24.2) -0.30 <0.01
Higher scores indicate a better QoL
1 Effect size = negative effect size indicates worse QoL in the group on dexamethasone. Positive effect size indicates better QoL in the group on 
dexamethasone: 0.2 ≤ d < 0.5 = small effect; 0.5 ≤ d < 0.8 = moderate effect; d ≥ 0.8 = large effect.
2 Dexa + versus Dexa - at T1, Wilcoxon signed ranks test
3 Dexa + versus Dexa - at T2, T-test for paired samples
* significant difference T1 vs. T2Page 4 of 8
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regardless of being on (d = 0.65) or off (d = 0.42) dexam-
ethasone. Only a few differences between both risk groups
were noted. Children in the High Risk protocol scored sig-
nificantly lower on the CHQ the behaviour subscale at T2
during both periods (on dexamethasone p = 0.03 and off
dexamethasone p = 0.04). Parental emotional impact was
also stronger (i.e. lower CHQ score) at T2 for the High
Risk group (both on and off dexamethasone p < 0.05,
respectively).
Table 3: PedsQL™ 3.0 acute cancer module Child Form at T2 (n = 12)
Dexa + Mean (SD) Dexa – Mean (SD) Effect size1 p2
Total 67.7 (15.4) 73.6 (12.0) -0.38 NS
Pain 45.8 (23.4) 67.0 (30.5) -0.70 0.04
Nausea 75.0 (24.2) 71.4 (21.0) 0.15 0.04
Procedural Anxiety 77.8 (26.0) 78.0 (23.9) -0.01 NS
Treatment Anxiety 86.8 (22.6) 88.7 (20.8) -0.08 NS
Worry 62.5 (26.2) 75.6 (18.3) -0.5 0.02
Cognitive 56.3 (24.9) 73.1 (15.5) -0.67 0.01
Perceived physical appearance 60.4 (22.2) 63.7 (16.9) -0.15 NS
Communication 72.2 (32.8) 71.3 (27.9) -0.03 NS
Higher scores indicate a better QoL
1 Effect size = negative effect size indicates worse QoL in the group on dexamethasone. Positive effect size indicates better QoL in the group on 
dexamethasone: 0.2 ≤ d < 0.5 = small effect; 0.5 ≤ d < 0.8 = moderate effect; d ≥ 0.8 = large effect.
2 Wilcoxon signed ranks test
Table 4: Child Health Questionnaire Parent Form 50
T1 (n = 15) T2 (n = 37)
Dexa + Mean (SD) Dexa – Mean (SD) Effect Size1 p2 Dexa + Mean (SD) Dexa – Mean (SD) Effect size1 p3
Physical Functioning 63.3# (15.0) 82.2# (13.3) -1.26 <0.01 47.8#^(24.0) 72.4#^(23.6) -1.03 <0.01
Role Limitations: 
emotional/
behaviour
60.7# (33.6) 93.7 (9.5) -0.98 0.01 41.1#^(30.2) 76.3# (25.1) -1.17 <0.01
Role Limitations: 
physical
51.1# (20.4) 85.7# (14.4) -1.70 <0.01 43.2# (25.0) 69.4# (29.5) -0.89 <0.01
Bodily Pain 56.0# (18.4) 66.7# (16.3) -0.58 0.05 43.8# (18.0) 64.3# (22.3) -0.92 <0.01
General Behaviour 59.5# (16.6) 76.9 (16.9) -1.03 0.01 55.8# (14.0) 68.9# (13.8) -0.94 <0.01
Mental Health 59.7# (14.7) 74.7# (11.3) -1.02 <0.01 55.3# (17.0) 68.9# (14.2) -0.8 <0.01
Self-esteem 60.3# (15.2) 71.1# (13.4) -0.71 0.01 54.4# (20.3) 66.3# (16.9) -0.59 <0.01
General Health 
Perception
45.0# (19.1) 49.3# (12.2) -0.23 NS 43.5# (20.8) 46.4# (21.0) -0.14 NS
Parental Impact: 
emotional
54.4# (24.0) 62.8# (19.1) -0.35 NS 50.7# (24.4) 54.3# (26.7) -0.13 NS
Parental Impact: 
time
51.9# (27.1) 77.0# (17.1) -0.93 0.01 43.8# (30.9) 60.4# (31.8) -0.52 <0.01
Family Activities 56.3# (23.8) 75.8# (13.6) -0.82 <0.01 41.7# (23.5) 58.6# (20.0) -0.72 <0.01
Family Cohesion 74.7 (22.0) 75.0 (19.1) -0.01 NS 59.2#^(23.2) 67.2 (17.4) -0.34 <0.01
Physical Summary 
Score Z-score‡
30.6# (10.0) 42.2# (6.8) -1.16 <0.01 24.3#^(11.1) 33.5# (13.2) -0.70 <0.01
Psychosocial 
Summary Score Z-
score‡
39.0# (11.4) 51.0 (5.1) -1.05 0.01 34.5# (11.2) 44.4# (8.9) -0.88 <0.01
Higher scores indicate a better QoL
1 Effect size = negative effect size indicates worse QoL in the group on dexamethasone. Positive effect size indicates better QoL in the group on 
dexamethasone: 0.2 ≤ d < 0.5 = small effect; 0.5 ≤ d < 0.8 = moderate effect; d ≥ 0.8 = large effect.
2 Differences on and off dexamethasone, Wilcoxon signed ranks test
3 Differences on and off dexamethasone, T-test for paired samples
# significant difference with Dutch reference (p < 0.05)
^Significant difference T1 vs. T2 (p < 0.05)
‡ Physical and Psychosocial CHQ summary scores based on a factor-analytical model on U.S. population samples. A score of 50 represents the 
mean in the general U.S. population. Scores below/above 50 are below/above the average in the general U.S. population.Page 5 of 8
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This study demonstrated that children during treatment
for ALL experience a reduced QoL, as compared to healthy
children, which is further aggravated by the use of dexam-
ethasone. This concords with results found in earlier stud-
ies on the effect of corticosteroids on children during
cancer treatment. [13,15] Yet this is the first study to spe-
cifically assess the second year of ALL treatment and to
include disease (i.e. cancer) specific QoL measures rather
than only generic QoL questionnaires. This allows for
more detailed information regarding the affected
domains of QoL, including change over time and/or dif-
ferences between relevant time points.
QoL was not only significantly lower than Dutch popula-
tion norms, moreover children on active treatment for
ALL also have a reduced QoL in comparison to children
with other chronic diseases like asthma and, to a lesser
extend, ADHD. [26,27] Similar results were found
recently by Varni et al., in a comparative analysis of QoL
in several disease clusters using the PedsQL 4.0 generic
core scales. A large group of children with cancer (brain
tumours, ALL, non-Hodgkin's lymphoma, Wilm's
tumour, neuroblastoma and Hodgkin's lymphoma) and
their parents reported significantly lower QoL in compar-
ison to healthy children and a selection of other disease
clusters. [28] In our study QoL was similar at 2 time points
for most domains (see tables 2 and 4). For certain relevant
domains however, QoL deteriorated over time. During
maintenance treatment we found no improvement in
QoL at T2 for any (sub)score, as was found by Eiser et al
[15] during the first, most intensive, year of treatment.
The decline in QoL for certain items during the second,
less intensive year of treatment, might be related to an
increasing cumulative dose of corticosteroids. This under-
scores the importance of continuing close monitoring and
counselling of both child and family during the whole of
treatment.
In HR children, reported scores on cognitive functioning
were considerable lower than in NHR children, regardless
of the use of dexamethasone. An important difference
between both risk groups was total methotrexate dose and
frequency of intrathecal therapy. Methotrexate has been
associated with impaired neurocognitive functioning [29-
31] and might explain the morbidity in cognition. Of
course, no neuropsychological tests were performed and
interpretation of these results should be done with care.
Limitations of this study are the small number of partici-
pants at T1. The introduction of a new protocol (ALL-10)
at the start of this study limited the number of possible
participants. Furthermore, the start of each dexametha-
sone period was accompanied by one dose of intravenous
vincristine, followed by a second vincristine dose one
week later. As vincristine is known to potentially have
neurotoxic side-effects, it might interfere with certain
aspects of QoL, such as pain and physical functioning.
Hence an interaction between dexamethasone and vinc-
ristine on QoL can not be ruled out entirely. The study
design (separate questionnaires referring to periods on
and off dexamethasone) and parental counselling on
potential side-effects of dexamethasone as part of usual
care, might attend respondents to differences that would
otherwise go unnoticed, causing bias. Although parents
were instructed to assess both periods on and off dexame-
thasone independently, the response may have been
flawed by sending the questionnaires in one single mail-
ing and by the fact that parents were not strictly instructed
to fill out questionnaires at the end of each period. In this
study, parental and self rating of QoL did not differ statis-
tically. The problem of proxy respondents is a widely
debated issue in literature, with an overall consensus that
children should be involved in QoL appraisal whenever
possible. [32-34] If more self reports could have been
obtained in this study, results might have been different.
This might be addressed in future studies. However, since
the peak incidence of childhood ALL is in young children,
obtaining self reports will be a continuing problem in
QoL studies during treatment.
Although it would have interesting to compare dexameth-
asone with prednisone, unfortunately the Dutch national
ALL-9 treatment protocol does not allow for randomisa-
tion to different glucocorticosteroids and applied dexam-
ethasone only.
Conclusion
Although it has been suggested that impaired quality of
life during cancer treatment in children is the effect of
treatment as a whole, rather than the specific effect of var-
ious components (e.g. corticosteroids) [15], the results of
this study suggest that dexamethasone probably plays an
important (and possibly underestimated) role. The suc-
cess of advancement in oncology is best illustrated with
the reduction of mortality in childhood ALL. Therefore
increasing attention can and should be given to the emo-
tional burden of childhood ALL for both the patient and
family. Treatment for ALL adversely affects all aspects of
quality of life and, although the effect of other therapeutic
agents can not entirely be ruled out, corticosteroids seem
to have an additional negative effect. Counselling and
coping of children and their parents with regard to the
possible effects of corticosteroids is therefore essential to
help them improve quality of life. The reduction of
adverse effect of maintenance chemotherapy on QoL in
childhood ALL in general, and of dexamethasone in par-
ticular, should therefore be subject of further studies with-
out jeopardising the cure-rate.Page 6 of 8
(page number not for citation purposes)
Health and Quality of Life Outcomes 2008, 6:103 http://www.hqlo.com/content/6/1/103Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MV: coordination of the study, gathering and processing
of data (questionnaires), performed the statistical analy-
ses and drafting of manuscript. RL: coordination of the
study, gathering and processing of data (questionnaires),
performed the statistical analyses, drafting and revising of
manuscript. JH: participated in the design of the study and
helped to draft the manuscript. MG: participated in the
coordination of the study, acquisition of data and helped
to draft the manuscript. BV: participated in the coordina-
tion of the study, acquisition of data and helped to draft
the manuscript.
GK: conceived the study, participated in its design and
coordination, assisted the statistical analysis, helped to
draft the manuscript. RG: conceived the study, partici-
pated in its design and coordination, assisted the statisti-
cal analysis, helped to draft and revise the manuscript. MV
and RL have both contributed equally to the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
None
References
1. Eiser C, Vance YH, Horne B, Glaser A, Galvin H: The value of the
PedsQLTM in assessing quality of life in survivors of child-
hood cancer.  Child Care Health Dev 2003, 29:95-102.
2. Eiser C, Eiser JR, Stride CB: Quality of life in children newly diag-
nosed with cancer and their mothers.  Health QualLife Outcomes
2005, 3:29.
3. Speechley KN, Barrera M, Shaw A, Morrison HI, Maunsell E: Health
related Quality of Life among child and adolescent survivors
of childhood cancer.  Journal of Clinical Oncology 2006,
24:2536-2543.
4. Waters EB, Wake MA, Hesketh KD, Ashley DM, Smibert E: Health-
related quality of life of children with acute lymphoblastic
leukaemia: comparisons and correlations between parent
and clinician reports.  Int J Cancer 2003, 103:514-518.
5. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K,
Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg
ME: Dexamethasone versus prednisone and daily oral versus
weekly intravenous mercaptopurine for patients with stand-
ard-risk acute lymphoblastic leukemia: A report from the
Children's Cancer Group.  Blood 2003, 101:3809-3817.
6. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Ham-
mond GD, Bleyer WA: Children's cancer group trials in child-
hood acute lymphoblastic leukemia: 1983–1995.  Leukemia
2000, 14:2223-2233.
7. Veerman AJP, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan
GAM, Solbu G, Suciu S, Van Wering ER, Berg AVDD Van den: High
cure rate with a moderately intensive treatment regimen in
non-high-risk childhood acute lymphoblastic leukemia:
Results of protocol ALL VI from the Dutch Childhood
Leukemia Study Group.  Journal of Clinical Oncology 1996,
14:911-918.
8. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C,
Sinks L, Chevalier L, Maurer HM, Koch K, et al.: Lower incidence of
meningeal leukemia when prednisone is replaced by dexam-
ethasone in the treatment of acute lymphocytic leukemia.
Medical and pediatric oncology 1991, 19:269-275.
9. Stuart FA, Segal TY, Keady S: Adverse psychological effects of
corticosteroids in children and adolescents.  Archives of Disease
in Childhood 2005, 90:500-506.
10. Soliday E, Grey S, Lande MB: Behavioral effects of corticoster-
oids in steroid-sensitive nephrotic syndrome.  Pediatrics 1999,
104:e51.
11. Kayani SSDC: Adverse behavioral effects of treatment for
acute exacerbation of asthma in children. A comparison of
two doses of oral steroids.  Chest 2002, 122:624-628.
12. McGrath P, Pitcher L: 'Enough is enough': qualitative findings on
the impact of dexamethasone during reinduction/consolida-
tion for paediatric acute lymphoblastic leukaemia.  Support-
Care Cancer 2002, 10:146-155.
13. Barr RD, Petrie C, Furlong W, Rothney M, Feeny D: Health-related
quality of life during post-induction chemotherapy in chil-
dren with acute lymphoblastic leukemia in remission: An
influence of corticosteroid therapy.  International journal of oncol-
ogy 1997, 11:333-339.
14. Hinds PS, Hockenberry MJ, Gattuso JS, Srivastava DK, Tong X, Jones
H, West N, McCarthy KS, Sadeh A, Ash M, Fernandez C, Pui CH:
Dexamethasone alters sleep and fatigue in pediatric patients
with acute lymphoblastic leukemia.  Cancer 2007,
110:2321-2330.
15. Eiser C, Davies H, Jenney M, Stride C, Glaser A: HRQOL implica-
tions of treatment with dexamethasone for children with
acute lymphoblastic leukemia (ALL).  PediatrBlood Cancer 2006,
46:35-39.
16. Raat H, Bonsel GJ, Essink-Bot ML, Landgraf JM, Gemke RJBJ: Reliabil-
ity and validity of comprehensive health status measures in
children: The Child Health Questionnaire in relation to the
Health Utilities Index.  Journal of Clinical Epidemiology 2002,
55:67-76.
17. Landgraf JM, Abetz L, Ware JA: The CHQ user's manual Boston: The
health institute, New England Medical Center 1996; 2006. 
18. Barrera M, Gee C, Andrews GS, Armstrong CA, Saunders FE:
Health-related quality of life of children and adolescents
prior to hematopoietic progenitor cell transplantation:
Diagnosis and age effects.  Pediatric Blood and Cancer 2006,
47:320-326.
19. Raat H, Landgraf J, Oostenbrink R, Moll H, Essink-Bot M: Reliability
and validity of the Infant and Toddler Quality of Life Ques-
tionnaire (ITQOL) in a general population and respiratory
disease sample.  Qual Life Res 2007, 16:445-460.
20. Felder-Puig R, di Gallo A, Waldenmair M, Norden P, Winter A, Gad-
ner H, Topf R: Health-related quality of life of pediatric
patients receiving allogeneic stem cell or bone marrow
transplantation: Results of a longitudinal, multi-center study.
Bone Marrow Transplant 2006, 38:119-126.
21. Marchese VG, Chiarello LA, Lange BJ: Effects of physical therapy
intervention for children with acute lymphoblastic leukemia.
Pediatr Blood Cancer 2004, 42:127-133.
22. Meeske K, Katz ER, Palmer SN, Burwinkle T, Varni JW: Parent
proxy-reported health-related quality of life and fatigue in
pediatric patients diagnosed with brain tumors and acute
lymphoblastic leukemia.  Cancer 2004, 101:2116-2125.
23. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P: The Ped-
sQL in pediatric cancer: reliability and validity of the Pediat-
ric Quality of Life Inventory Generic Core Scales,
Multidimensional Fatigue Scale, and Cancer Module.  Cancer
2002, 94:2090-2106.
24. Cohen J: Statistical power analysis for behavioral sciences New York:
Academic press; 1977. 
25. Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting
changes in health status.  Medical care 1989, 27:S178-S189.
26. Asmussen L, Olson LM, Grant EN, Landgraf JM, Fagan J, Weiss KB:
Use of the child health questionnaire in a sample of moder-
ate and low-income inner-city children with asthma.  Am J
Respir Crit Care Med 2000, 162(4 Pt. 1):1215-1221.
27. Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA: Psychomet-
ric validation of the child health questionnaire (CHQ) in a
sample of children and adolescents with attention-deficit/
hyperactivity disorder.  Quality of Life Research 2005, 14:719-734.
28. Varni JW, CA L, TM B: Impaired health-related quality of life in
children and adolescents with chronic conditions: a compar-
ative analysis of 10 disease clusters and 33 disease catego-Page 7 of 8
(page number not for citation purposes)
Health and Quality of Life Outcomes 2008, 6:103 http://www.hqlo.com/content/6/1/103Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
ries/severities utilizing the PedsQL 4.0 Generic Core Scales.
Health Qual Life Outcomes 2007, 16:43.
29. Ochs J, Mulhern R, Fairclough D, Parvey L, Whitaker J, Ch'ien L,
Mauer A, Simone J: Comparison of neuropsychologic function-
ing and clinical indicators of neurotoxicity in long-term sur-
vivors of childhood leukemia given cranial radiation or
parenteral methotrexate: a prospective study.  J Clin Oncol
1991, 9:145-151.
30. Giralt J, Ortega J, Olive T, Verges R, Forio I, Salvador L: Long-term
neuropsychologic sequelae of childhood leukemia: compari-
son of two CNS prophylactic regimens.  Int J Radiat Oncol Biol
Phys 1992, 24:49-53.
31. Kerr J, Berg S, Blaney S: Intrathecal chemotherapy.  Crit Rev Oncol
Hematol 2001, 37:227-236.
32. Janse AJ, Gemke RJBJ, Uiterwaal CS, Tweel I Van der, Kimpen JLL, Sin-
nema G: Quality of life; patients and doctors don't always
agree: A meta analysis.  Journal of Clinical Epidemiology 2004,
57:661.
33. Parsons SK, Barlow SE, Levy SL, Supran SE, Kaplan SH: Health-
related quality of life in pediatric bone marrow transplant
survivors: according to whom?  Int J Cancer Suppl 1999, 12:46-51.
34. Theunissen NC, Vogels TG, Koopman HM, Verrips GH, Zwinderman
KA, Verloove-Vanhorick SP, Wit JM: The proxy problem: child
report versus parent report in health-related quality of life
research.  Quality of Life Research 1998, 7:387-397.Page 8 of 8
(page number not for citation purposes)
